SpecGX, LLC, et al.; Withdrawal of Approval of 30 Abbreviated New Drug Applications; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on March 29, 2024. The document announced the withdrawal of approval of 30 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of April 29, 2024. The document indicated that FDA was withdrawing approval of the following ANDAs after receiving withdrawal requests from Target Health LLC, U.S. Agent for CASI Pharmaceuticals, Inc., 450 Commerce Blvd., Carlstadt, NJ 07072: ANDA 076280, Tizanidine Hydrochloride (HCl) Tablets, Equivalent to (EQ) 2 milligrams (mg) base and EQ 4 mg base; ANDA 077021, Cilostazol Tablets, 100 mg; ANDA 077310, Cilostazol Tablets, 50 mg; ANDA 077517, Ondansetron HCl Tablets, EQ 4 mg base, EQ 8 mg base, and EQ 24 mg base; ANDA 206672, Entecavir Tablets, 0.5 mg and 1 mg; and ANDA 209550, Tenofovir Disoproxil Fumarate Tablets, 300 mg. Before FDA withdrew the approval of these ANDAs, Target Health LLC, informed FDA that it did not want the approval of the ANDAs withdrawn. Because Target Health LLC, timely requested that approvals of ANDAs 076280, 077021, 077310, 077517, 206672, and 209550 not be withdrawn, the approvals are still in effect. This notice corrects that error.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 120 (Friday, June 21, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Page 52062]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-13658]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-0020]
SpecGX, LLC, et al.; Withdrawal of Approval of 30 Abbreviated New
Drug Applications; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a notice
that appeared in the Federal Register on March 29, 2024. The document
announced the withdrawal of approval of 30 abbreviated new drug
applications (ANDAs) from multiple applicants, withdrawn as of April
29, 2024. The document indicated that FDA was withdrawing approval of
the following ANDAs after receiving withdrawal requests from Target
Health LLC, U.S. Agent for CASI Pharmaceuticals, Inc., 450 Commerce
Blvd., Carlstadt, NJ 07072: ANDA 076280, Tizanidine Hydrochloride (HCl)
Tablets, Equivalent to (EQ) 2 milligrams (mg) base and EQ 4 mg base;
ANDA 077021, Cilostazol Tablets, 100 mg; ANDA 077310, Cilostazol
Tablets, 50 mg; ANDA 077517, Ondansetron HCl Tablets, EQ 4 mg base, EQ
8 mg base, and EQ 24 mg base; ANDA 206672, Entecavir Tablets, 0.5 mg
and 1 mg; and ANDA 209550, Tenofovir Disoproxil Fumarate Tablets, 300
mg. Before FDA withdrew the approval of these ANDAs, Target Health LLC,
informed FDA that it did not want the approval of the ANDAs withdrawn.
Because Target Health LLC, timely requested that approvals of ANDAs
076280, 077021, 077310, 077517, 206672, and 209550 not be withdrawn,
the approvals are still in effect. This notice corrects that error.
FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 301-
796-3471, <a href="/cdn-cgi/l/email-protection#d895b9aaacb0b9f696bfada1bdb698bebcb9f6b0b0abf6bfb7ae"><span class="__cf_email__" data-cfemail="7b361a090f131a55351c0e021e153b1d1f1a55131308551c140d">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In the Federal Register of Friday, March 29,
2024 (89 FR 22155), appearing on page 22155 in FR Doc. 2024-06730, the
following correction is made:
On page 22155, in the table, the entries for ANDAs 076280, 077021,
077310, 077517, 206672, and 209550 are removed.
Dated: June 17, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-13658 Filed 6-20-24; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.